(1R,2R)-2-({4'-[({[2-fluoro-5-(trifluoromethyl)phenyl]amino}carbonyl)amino]-1,1'-biphenyl-4-yl}carbonyl)cyclopentanecarboxylic acid | 959122-68-0

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (1R,2R)-2-({4'-[({[2-fluoro-5-(trifluoromethyl)phenyl]amino}carbonyl)amino]-1,1'-biphenyl-4-yl}carbonyl)cyclopentanecarboxylic acid
• 英文别名: (1R,2R)-2-({4-[4-({[2-fluoro-5-(trifluoromethyl)phenyl]carbamoyl}amino)phenyl]phenyl}carbonyl)cyclopentane-1-carboxylic acid；(1R,2R)-2-[4-[4-[[2-fluoro-5-(trifluoromethyl)phenyl]carbamoylamino]phenyl]benzoyl]cyclopentane-1-carboxylic acid
• CAS: 959122-68-0
• 化学式: C₂₇H₂₂F₄N₂O₄
• 分子量: 514.476
• InChiKey: WOHJKWLVYWTJDJ-NHCUHLMSSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.3
• 重原子数：
  37
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  95.5
• 氢给体数：
  3
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  (1R,2R)-2-({4'-[({[2-fluoro-5-(trifluoromethyl)phenyl]amino}carbonyl)amino]-1,1'-biphenyl-4-yl}carbonyl)cyclopentanecarboxylic acid methyl ester 在 lithium hydroxide 作用下， 以 四氢呋喃 、 水 为溶剂， 生成 (1R,2R)-2-({4'-[({[2-fluoro-5-(trifluoromethyl)phenyl]amino}carbonyl)amino]-1,1'-biphenyl-4-yl}carbonyl)cyclopentanecarboxylic acid
  参考文献：
  名称：

  Validation of Diacyl Glycerolacyltransferase I as a Novel Target for the Treatment of Obesity and Dyslipidemia Using a Potent and Selective Small Molecule Inhibitor

  摘要：

  A highly potent and selective DGAT-1 inhibitor was identified and used in rodent models of obesity and postprandial chylomicron excursion to validate DGAT-1 inhibition as a novel approach for the treatment of metabolic diseases. Specifically, compound 4a conferred weight loss and a reduction in liver triglycerides when dosed chronically in DIO mice and depleted serum triglycerides following a lipid challenge in a dose-dependent manner, thus, reproducing major phenotypical characteristics of DGAT-1(-/-) mice.

  DOI：

  10.1021/jm7013887

文献信息

• Inhibitors of diacylglycerol O-acyltransferase type 1 enzyme
  申请人：Kym R. Philip

  公开号：US20080015227A1

  公开（公告）日：2008-01-17

  The present invention relates to compounds of formula (I). wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , m, n, p and q are defined herein Pharmaceutical compositions and methods for treating DGAT-1 related diseases or conditions are also disclosed.

  本发明涉及式(I)的化合物。其中R1、R2、R3、R4、R5、R6、m、n、p和q在此处定义。还公开了用于治疗DGAT-1相关疾病或症状的药物组合物和方法。